Precision Medicine Online59 分钟
Actinium Launches Clinical Program to Test Actimab-A With PD-1 Inhibitors in Solid Tumors
The firm will assess whether adding its CD33-targeted radiotherapy Actimab-A to PD-1 inhibitors will benefit patients more than PD-1 inhibitors alone.